Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regado Biosciences, a developer of two-component drug systems, has appointed Steven Zelenkofske as its new senior vice president of clinical and medical affairs and chief medical officer.
Subscribe to our email newsletter
Most recently, Dr Zelenkofske served as vice president of cardiovascular and thrombosis medical unit for US at Sanofi-Aventis Pharmaceuticals and, prior to this, as vice president of clinical sciences and chief patient safety officer for Boston Scientific Corporation’s cardiac rhythm management group.
Regado has recently completed enrollment in a Phase IIa clinical study of REG1 in patients undergoing elective percutaneous coronary intervention.
David Mazzo, president and CEO of Regado, said: “Steven has led clinical programs for more than 15 development-stage and commercialized cardiovascular products during his pharmaceutical career and has extensive experience as a principal investigator on a number of important trials in cardiovascular medicine. His track record will be critical as Regado advances its lead therapeutic candidate, the REG1 anticoagulation system, through late-stage clinical development.”